Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Published Date: 18 Feb 2023

Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

After two years, a significant left nasal obstruction was finally diagnosed.

2.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

3.

Implant-based reconstruction linked to increased risk of breast lymphomas

4.

As pesticides and wildfires rise, kids with cancer need resources

5.

High weight and obesity are associated with poor outcomes in leukemia treatment.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot